Skip to main content
Wiley Open Access Collection logoLink to Wiley Open Access Collection
. 2026 Jul 12;32(6):1350–1358. doi: 10.1111/hae.70359

Symptoms, Diagnosis, and Treatment for Women and Girls With Hemophilia: A Narrative Review

Sam Hirniak 1, Carla Samuel 1, Faria Aditi 1, Haya Abu Ghazaleh 1, Dawn Rotellini 2, Menaka Pai 3, Andrea Edginton 1,✉
PMCID: PMC13754621  PMID: 42438295

ABSTRACT

Introduction

Hemophilia is an X‐linked bleeding disorder previously thought to present only in men. This sentiment is rapidly changing as the information around women and girls’ experiences of bleeding symptoms has evolved, sparking intense discussion among researchers, clinicians, patients, and patient advocates regarding appropriate nomenclature.

Aim

The primary objective of this narrative review is to build a comprehensive understanding of how women with hemophilia experience symptoms, how those symptoms are managed, navigate barriers to care, as well as discuss what can be done to alleviate barriers amongst this population.

Methods

This is a qualitative narrative review which incorporates literature search strategies alongside testimonial from patient advocates to inform study priorities.

Results

This review identified multiple barriers to care for women and girls with hemophilia, including recognizing symptoms of abnormal bleeding, feeling comfortable asking for help, dealing with stigma from clinicians, getting an appropriate referral, accessing screening, facing challenges along the diagnostic pathway, and receiving treatment for symptoms. Another challenge is the wide variety of places a woman or girl may go to seek care for her bleeding symptoms, including primary care providers, gynecologists, hematologists, emergency medicine physicians, and rheumatologists.

Conclusion

We conclude that while important strides have been made in this area in research and understanding, gaps remain. The research gaps in the differential symptom presentation when compared to men, potential efficacy and effectiveness of treatments in women as well as gender based behavioral difference are crucial to improving care and mitigating barriers for this cohort.

Key Points

  • This literature review combines information on symptoms, blood and genetic screening, diagnosis, treatment, current barriers to care, and next steps into a comprehensive perspective of the current available research. Evidence indicates that women with hemophilia are more likely than men to experience concerns related to family planning. In addition, women, in general, are more likely to engage in presenteeism rather than absenteeism when managing menstrual symptoms, attending work or school while unwell, which can result in reduced productivity. While screening techniques exist, novel rapid assays are being developed that could be more effective for screening women, particularly those who require multiple screenings before a diagnosis can be established.

  • This can be combined with increased screening protocols to systematically identify carriers within families affected by hemophilia to ensure diagnosis. However, current efforts tend to focus on women of childbearing age, although premenarchal girls also experience hemophilia‐related symptoms.

  • The modalities of care for women and girls with hemophilia are numerous including pharmaceuticals such as factor replacement therapy, desmopressin, antifibrinolytic drugs, nonfactor therapy, and hormonal therapy. Additionally, assistance from physiotherapists, rheumatologists, and orthopedic surgeons can help manage joint related complications. Even with many care options, significant barriers to care persist, including the minimization of symptoms, avoidance of medical care, normalization of symptoms due to family history, and difficulties accessing care because of caregiving responsibilities.

  • Existing care structures should be leveraged to provide better support for women and girls with hemophilia and symptomatic carriers. These could include more information provided within caregiving support groups, changes in guidelines, and wider understanding from the medical community as women and girls with hemophilia may seek assistance for their symptoms at a wide variety of clinical locations.

Keywords: girl, hemophilia b gene, hemophilia carrier, medicine, mild hemophilia a, moderate hemophilia a, narrative, severe hemophilia a

1. Background

Due to hemophilia's history as an X‐linked genetic disorder, women and girls with hemophilia (and carriers) have been stigmatized as not experiencing symptoms, and thus not requiring care. This spurred recent discussion into an updated nomenclature for these individuals which has resolved some confusion regarding the differences between a carrier (asymptomatic or symptomatic) and a woman with hemophilia (mild, moderate, severe) [1, 2, 3]. The International Society on Thrombosis and Haemostasis (ISTH) and the World Federation of Hemophilia (WFH) updated their terminology, and Figure 1 provides a flowchart illustrating these terms [1, 2, 3]. Terminology in this article is used in accordance with the context of the information presented. Due to evolving nomenclature, earlier studies may exhibit selection bias, which could result in the exclusion of asymptomatic or symptomatic carriers from research classified under “women with hemophilia.” Additionally, while this nomenclature was chosen for this article, the authors recognize that not all who carry an X‐chromosome and/or have the ability to menstruate identify as women or girls. This article aims to include all persons with the ability to menstruate as this is the main symptom defined for women with hemophilia in the ISTH nomenclature. However, for simplification in reading this article will refer to women and girls with hemophilia (WGHC).

FIGURE 1.

FIGURE 1

Diagram of new nomenclature for women with hemophilia and carriers of hemophilia [1, 2, 3].

The assumption that all previously named carriers were asymptomatic, led to a lack of research into the health impacts and outcomes for WGHC [2]. Beginning in 1988, for each male person with hemophilia, there are expected to be three to five carriers, indicating a significant population of individuals who may need medical assistance [4]. It is unknown what percentage of carriers are expected to have a hemophilia diagnosis. As of 2022 in the Annual Global Survey by the WFH, women represent only 3% of hemophilia A and 6% of hemophilia B diagnoses globally, while their clinical needs remain distinct and underserved [5, 6].  Carriers may exhibit symptoms (such as bleeding and reduced joint range of motion) even when factor activity levels exceed 40%, adding additional complexity to researching WGHC [2]. As with many chronic disorders, individuals with hemophilia do not experience symptoms continuously, obfuscating research and diagnosis. Existing databases estimate anywhere from 19%–23% of women who received care at a hemophilia treatment center, had factor levels below 40% [7].

This article integrates recent advances in the field with historical understanding of the disorder to provide a comprehensive overview on the pathways to screening, diagnosis, and treatment, as well as the barriers faced by women and girls at each stage of the process. For a holistic view, we have incorporated the perspectives of patients, their advocates, their physicians, and researchers to ensure a comprehensive look at current experiences. Included in this review, we consider the entire cohort of women who may experience hemophilia‐related symptoms, regardless of their factor levels, official diagnosis status, or the time at which they first exhibited symptoms. This is due to barriers to diagnosis and care that may result in some women with hemophilia being classified as carriers or left unclassified.

2. Symptoms

This paper begins with a discussion on the manifestations of hemophilia in women and girls, as more severe symptoms are often required prior to the initiation of diagnostic procedures or screening. 37% of women who carry the hemophilia gene have a bleeding tendency [4]. Between August 2023 and February 2024, a study compared the bleeding profiles and quality of life of 80 women and girls with hemophilia to those of individuals with other bleeding disorders [8].Four main categories of symptoms are prevalent: non‐gynecological bleeding symptoms, gynecological symptoms, procedure‐based symptoms, and mental health‐related symptoms [1, 2, 4, 5, 8, 9, 10, 11, 12, 13]. For quick reference, the major symptoms are presented within Figure 2.

FIGURE 2.

FIGURE 2

Image of the possible symptoms experienced by women and girls with hemophilia and carriers.

2.1. Non‐Gynecological Bleeding Symptoms

In a 2006 study by Plug et al. of 274 carriers showed a median clotting factor of 0.6IU/mL and lower clotting factor was found to be associated with prolonged bleeding [14]. Additionally, even mildly reduced clotting factor levels (between 0.41 and 0.6IU/mL) were associated with bleeding profiles [14]. In a more recent study, 30% of women with hemophilia (A or B) report bleeding symptoms (in all categories of bleeding including gynecological bleeding) [8]. Underreporting may have occurred in this data set because of the short duration and/or the challenges of objectively identifying subclinical bleeds. However, the study has been extended to five years and will provide annual bleed rate data in the future.

Joint bleeding and subclinical joint bleeding can lead to joint‐related symptoms. A 2023 study utilizing validated clinical assessment tools, showed that WGHC reported a higher frequency of joint‐related symptoms, such as joint pain and swelling, compared with individuals with no relation to hemophilia, with symptoms observed in 53% of women with hemophilia [8, 15]. While WGHC reported more joint symptoms than the controls, the study did not show more evidence of joint damage on the ultrasound evaluations [8, 15].

2.2. Gynecologic and Obstetric Symptoms

WGHC are expected to be at higher risk of gynecologic bleeding‐related symptoms than other women. An internet‐based study amongst women in Europe found that 27.2% of women have heavy menstrual bleeding (HMB) [16]. Of these women, 46% never consulted a physician, indicating normalization and/or stigmatization of symptoms can be a significant hurdle in access to care in the population of women at large [16]. HMB contributes to iron deficiency anemia, resulting in severe negative impacts on an individual's quality of life [8],[17]. In a study of women with hemophilia, the most reported bleeding symptom was HMB, at 26.4% [8].

Post‐partum hemorrhage is the leading cause for post‐natal mortality in the world [18, 19]. One percent of WGHC reported antepartum hemorrhage, 1% reported post‐abortion bleeding, and 1% reported postpartum hemorrhage during the six‐month study [8]. It is unclear how many women were pregnant during the study period, although every woman had experienced childbirth previously [8]. Additionally, other studies show 22% of WGHC who undergo childbirth experience excessive bleeding after delivery [4, 20]. A recent systematic review suggests a high risk for postpartum hemorrhage in those with the hemophilia, but also highlights generally poor quality evidence and limited discussion of peripartum management in carriers, underscoring the need for larger cohort studies [21]. Fortunately, recent findings indicate that prophylaxis at delivery can significantly reduce blood loss and help prevent postpartum hemorrhage in WGHC [22, 23].

2.3. Other Procedure‐Based Symptoms

Women and girls with hemophilia have more severe post‐surgical bleeding symptoms than those without the condition, including excessive pain and bleeding after tooth extraction in carriers of hemophilia A and B (43%), tonsillectomy (45%) and other surgical procedures (30%) [4, 20].

2.4. Mental Health Symptoms

In 2024, a cross‐sectional study compared patient‐reported outcomes in men (n = 118) and women (n = 21) diagnosed with hemophilia A or B, finding that women had a higher proportion of mild disease status [12]. Women in this study were more likely than men to report depression, anxiety and fatigue [12]. From our discussion with patient advocates, carrier status commonly goes hand in hand with caregiving duties. Caregivers of individuals with hemophilia often experience additional mental burden from coordinating treatment schedules, travelling long distances to acquire medical care, and managing medication supplies [8],[24]. The intersection of caregiving and disease‐related stress in WGHC is not well represented in the literature.

3. Screening

Proactive screening is crucial for detecting and diagnosing WGHC [25]. Factor level testing is the most common diagnostic method. Babies can be screened shortly after birth when there is a family history of hemophilia or when prolonged bleeding occurs during routine procedures [26]. The US Centers for Disease Control and Prevention estimates that one in three people with hemophilia have no known family history of the disorder, indicating that screening based only on family history may miss a substantial portion of affected individuals [26].

Genetic testing is the most reliable method for detecting factor VIII or IX mutations, and next‐generation sequencing could further improve diagnostic accuracy [15]. In addition, researchers are developing rapid assays targeting specific gene mutations to accelerate diagnostic timelines [27]. While genetic testing is the most reliable method, there may be financial and insurance related barriers when accessing this care. This is especially true for women who experience normal factor levels. Comprehensive clinical evaluations, such as the International Society on Thrombosis and Hemostasis Bleeding Assessment Tool, are also crucial for the accurate detection of bleeding disorders [5].

A novel, ongoing, single hemophilia treatment center (HTC)‐site study, is systematically identifying all potential carriers within families of individuals with hemophilia [25]. As of 2023, 44% of the cohort has been screened, confirming carrier status in 73% of the mothers, sisters and daughters [25]. This study is only examining individuals of childbearing age, highlighting a significant gap in research on carriers, which largely focuses on their potential to pass on hemophilia rather than their own experiences and health outcomes [25].

4. Treatment Options

Once a WGHC receives a diagnosis, a wide variety of treatment options may be available to them, though there are very few clinical practice guidelines that adequately address this population. Treatment options can be divided into bleed prevention, bleed management, and joint care. The WFH Guidelines of care for those with hemophilia are well‐stated and easily accessible [28]. One of the main guidelines that specifically discusses women with inherited bleeding disorders is during the stages of pregnancy and perinatal management [29]. However, some patients find these documents do not include enough detail on the overall experiences of WGHC. For quick reference, treatment options are presented within Figure 3.

FIGURE 3.

FIGURE 3

Image of the treatment options for women and girls with hemophilia and carriers.

4.1. Bleed Prevention

Prophylactic use of factor concentrates for factor replacement therapy (FRT) or non‐factor therapies are the standard treatment for moderate to severe forms of bleeding disorders [30]. There is discussion about expanding this treatment to those with mild hemophilia, which would include most women with hemophilia. A study reported that women diagnosed with hemophilia receive episodic FRT (90.5%), higher than boys and men with mild hemophilia, of whom 70% use episodic treatment for bleeds [12, 31]. Symptomatic carriers were not included [12]. We cannot determine what proportion of WGHC have access to prophylactic FRT. According to the guidelines laid out by the National Bleeding Disorders Foundation, pregnant WGHC should receive FRT at the time of delivery if factor levels are below 50% [29]. A recently published abstract showing results from the Pregnancy and Inherited Bleeding Disorders Study indicates that prophylactic care through FRT can achieve similar postpartum outcomes to those who do not have low factor levels [22].

Desmopressin can also be utilized for those with mild‐moderate hemophilia A [32, 33]. This can reduce or eliminate the need for FRT during minor bleeding episodes or surgical procedures [28]. Desmopressin is included within the National Bleeding Disorders Foundation's guidelines for women and girls with hemophilia during pregnancy for invasive procedures [29]. While desmopressin was previously thought of as unsafe during pregnancy, a 2023 systematic review in those with inherited bleeding disorder has confirmed that desmopressin is generally safe during pregnancy [34]. Numerous other studies have corroborated that desmopressin can be safe and effective during pregnancy for the general population [21, 32, 33, 34]. It is recommended to complete a test dose of desmopressin as there can be wide interindividual variability in dose response. This updated knowledge is crucial as some of the most dangerous symptoms, such as postpartum hemorrhage, occur during this time. Desmopressin may be inappropriate for those with severe hemophilia A due to insufficient factor VIII stores. For the majority of WGHC who show non‐severe presentations, desmopressin is a reasonable option [31].

Other prophylactic interventions include tranexamic acid and other antifibrinolytic drugs, which are prescribed to treat menorrhagia and mucosal bleeding [35, 36]. There has been theoretical concern that when used for HMB, tranexamic acid could increase the risk of venous thromboembolic disease. The evidence in numerous studies has not supported this [36, 37, 38].

Additionally, a 2024 randomized control study evaluated post‐partum hemorrhage risk after prophylactic tranexamic acid in high‐risk pregnant women [39]. These women delivered by cesarean section and the study found that those given prophylactic tranexamic acid were 41% less likely to have postpartum hemorrhage [39]. The study did not specify whether its inclusion criteria included individuals with hemophilia. It stands to reason that since women with (or carriers of) hemophilia may be at higher risk of postpartum hemorrhage, prophylactic care with factor products, desmopressin, or tranexamic acid could prevent postpartum hemorrhage.

Emicizumab, a non‐factor replacement therapy, was recently approved for use in those with hemophilia as a prophylactic option [40, 41, 42, 43]. While we could not find any studies which evaluated emicizumab for use in WGHC, emicizumab could be considered for use within this population.

Other options to manage HMB may include hormonal therapy, such as combined oral contraceptives and levonorgestrel‐releasing intrauterine devices (LIUDs), and surgical options, such as endometrial ablation and hysterectomy [5]. The patient's values and preferences around fertility should be centered when deciding between these options.

4.2. Joint Health

Subclinical joint bleeding may contribute to hemophilic arthropathy if left untreated. Treatments from other disciplines, particularly rheumatology, physical therapy, and orthopedics, can help manage hemophilic arthropathy. Anti‐inflammatory drugs derived from rheumatoid arthritis therapy are studied to prevent joint degeneration. COX‐2 inhibitors are the most used anti‐inflammatory agents in hemophilic arthropathy; they are recommended by WFH guidelines for managing synovitis and chronic musculoskeletal pain, given their anti‐inflammatory and analgesic effects without the bleeding risk conferred by platelet inhibition [44, 45]. Short courses of oral corticosteroids and intra‐articular corticosteroid injections are also used for acute flares, although high‐quality randomized data are limited [44, 45]. Minimally invasive surgical procedures have improved results for women who require joint replacements [15]. It is possible that some joint surgeries could potentially be avoided through proactive FRT, as shown in men [46].

5. Health and Social Outcomes

Both men and women with hemophilia reported identical health‐related quality of life scores (0.8 with standard deviations of 0.1 for women and 0.2 for men) on a EQ‐5D‐5L assessment [12]. However, there were key differences in the contributing factors [12]. WGHC are more likely to report depression, anxiety, and fatigue as compared to their male counterparts [12]. Scores of distress were similar between the sexes, with women reporting a hemophilia‐related distress score of 35.5, and men reporting a score of 35.1, with almost identical standard deviation for the scores,16.7 for women and 16.8 for men [12]. Yet, once these scores were adjusted to limit bias, the distress scores were significantly higher in women compared to men [12]. In this study, 37% of women had an income category of over 100K USD compared to only 15.5% of men, clarifying the need for adjustment [12]. It is possible that women with higher incomes are more likely to have access to health care and laboratory diagnostics. Additionally, some of these differences could be attributed to potential selection bias as women are more likely to have milder forms of hemophilia than men. The relationship between socioeconomic status and access to care for this cohort remains unclear. Additional research is needed to ensure that everyone with hemophilia has equal access to diagnosis and treatment.

Women were more likely to feel better about sports and leisure, as well as about treatment, than men [12]. Women were, however, much more impacted by concerns around family planning when compared to men with hemophilia [12]. Moreover, hemophilia has negatively affected the education of both men and women [9]. Previous work has shown that men with mild hemophilia miss an average of 17 days per year of school or work due to their hemophilia [31]. The impact of hemophilia on work and school is currently not well‐defined for WGHC.

However, the effect of menstruation‐related symptoms on age‐dependent productivity loss has been evaluated [47]. The average absenteeism was only 1.3 (±5.9) days per year [47]. More commonly reported was presenteeism, when individuals attend work or school while unwell, leading to an average of 8.9 (±10.6) days of lost productivity [47]. Absenteeism and presenteeism were highly associated with abdominal pain intensity [47]. Any effects on work or school could potentially be compounded by caregiving responsibilities, a lack of support for—or outright stigmatization of—bleeding symptoms, and feelings of isolation.

6. Addressing Barriers to Care and Next Steps

Despite pivotal advances in hemophilia treatment in recent years, WGHC still face considerable challenges. Women with hemophilia are underrepresented in clinical trials, which limits the available data for evidence‐based decision‐making [48]. Within clinical trials, there is a lack of focus on quantifying menstrual‐related symptoms, leading to further marginalization [48]. Additionally, medication access is subject to disparities, particularly in low‐income communities [5]. Advocating for expanded inclusion in research and awareness campaigns is critical to address these disparities and ensuring equal access to care for all with hemophilia.

Unfortunately, WGHC often tend to trivialize their bleeding and do not vocalize it, which is a cause of underdiagnosis and could potentially impact any survey results [8]. This minimization frequently compounds with medical avoidance, as individuals seek to avoid placing additional burdens on their families [8]. One potential concern with recognizing symptoms is that, due to the familial nature of the disease, normalization of WGHCs’ bleeding may occur within the family dynamic, leading to medical avoidance. Medical avoidance for menstrual symptoms could represent a significant gender‐based issue, as WGHC are often caregivers themselves; making their health needs more likely to be overlooked or deprioritized. Women with hemophilia report feeling like their symptoms are not “significant” enough to seek care when compared to their male relative's symptoms, even though evidence suggests their symptoms are significant [1, 2, 4, 5, 8, 9, 10, 11, 12, 13]. This behavioral limitation is something clinicians should be aware of and ask appropriate questions when determining if a carrier is symptomatic or asymptomatic. Understanding the complex interplay of challenges between WGHC and caregiving is crucial to improving their outcomes.

Regular systematic blood testing combined with newer testing methods, could significantly enhance the accessibility of screening for WGHC [25, 27]. Anecdotally, WGHC reported they were required to undergo multiple factor level testing to receive their diagnosis with highly varying factor levels shown. Each factor assay type will display distinct factor levels which complicates comparison and can make longitudinal comparison difficult. For those with hemophilia B, there is significant variability in bleeding symptoms, even among women with the same genetic mutation, and bleeding is not always concordant with factor levels [49, 50]. In 1988, there was some sparse discussion on the variation of the activity of factor VIII throughout the menstrual cycle [51]. A more recent systematic review on HMB and clotting factors looked at 2158 articles and found that women with HMB tended to have higher levels of factor 8 and factor 9 compared to those without HMB [52]. There were not enough luteal phase measurements to evaluate clotting factor concentration differences between the follicular and luteal phases for women with HMB [52]. However, no statistically significant difference was reported for women without HMB [52].

There is an existing roadmap to improve care for WGHC, as demonstrated by the extensive work done to mitigate symptoms and enhance screening, diagnosis, and treatment in men with hemophilia. In many countries, specialized HTCs already exist, many of which are part of a national network. WGHCs often have access to these centers through their family members with hemophilia, making proactive screening possible [25]. These organizations already offer individual and family‐level support. Changes in guidelines and norms could leverage these existing, well‐developed structures to provide care for WGHC with identified symptoms. Providing materials and support navigating through family and caregiving support groups on recognizing key signs and symptoms and knowing when to seek help themselves could be crucial in helping individuals feel more informed, supported, and less isolated.

Over the last five years, efforts to research WGHC have increased; however, gaps remain. There is a need for expansion of information in this area, particularly regarding screening, treatment and health outcomes. Additionally, much of the past research on treatment and screening focused on the role of these women and girls in transmitting the illness. This is evidenced by the practice of only screening reproductive‐age women and girls or focusing care delivery solely on the peripartum period. Hemophilia has a wide variety of potential impacts for women and girls outside of the peripartum period. Women and girls merit care regardless of their interest in or capacity for reproduction. We must continue to study the full experiences of these women and girls so that we can improve their quality of life in its entirety.

There also needs to be a greater understanding of hemophilia among the broader medical community, despite its formal classification as a rare disease. The impact of hemophilia can be widespread and highly damaging to an individual's health and quality of life. Many WGHC may approach a broad range of healthcare professionals for their bleeding symptoms; their path to diagnosis may not be straightforward. It is important that this work is a cross‐disciplinary education and community‐building effort, incorporating a wide array of clinical disciplines, as women may seek care at various locations. If they are adequately informed and empowered, many different types of healthcare professionals can have a substantial impact on the lives of women with hemophilia and symptomatic carriers.

7. Conclusion

Recently, increased attention has been drawn to the under‐recognition, underdiagnosis, and undertreatment of WGHC. Important questions remain regarding the differences in symptom profiles compared to men, both the efficacy and effectiveness of treatments, gender‐based behavioral differences in accessing care, and the absence of standardized screening and diagnostic approaches. Furthermore, additional work is needed to mitigate the existing barriers to care. Ongoing collaboration among researchers, policymakers, multidisciplinary medical professionals, and, most importantly, WGHC is essential to ensure optimal health outcomes.

Funding

D. Rotellini is from the National Bleeding Disorders Foundation (NBDF) which as an organization has received grants from: Bayer, BioMarin, CSL Behring, Genentech, Kedrion, Novo Nordisk, Pfizer, Sanofi, Takeda in the past 3 years.

Ethics Statement

Ethics approval was not sought for the present study because no datasets were generated or analyzed during the current study, and all data is discussed within it's published context.

Conflicts of Interest

The authors declare no conflicts of interest.

Data Availability Statement

Data sharing not appliable to this article as no datasets were generated or analyzed during the current study.

References

  • 1. Women and Girls with Hemophilia . 2023, WFH: Montreal. p. 1–24.
  • 2. Weyand A. C., Sidonio R. F. Jr, and Sholzberg M., “Health Issues in Women and Girls Affected by Haemophilia With a Focus on Nomenclature, Heavy Menstrual Bleeding, and Musculoskeletal Issues,” Haemophilia 28, no. S4 (2022): 18–25. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3. van Galen K. P., d'Oiron R., James P., et al., “A New Hemophilia Carrier Nomenclature to Define Hemophilia in Women and Girls: Communication From the SSC of the ISTH,” Journal of Thrombosis and Haemostasis 19, no. 8 (2021): 1883–1887. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4. Mauser Bunschoten E. P., van Houwelingen J. C., Sjamsoedin Visser E. J., van Dijken P. J., Kok A. J., and Sixma J. J., “Bleeding Symptoms in Carriers of Hemophilia A and B,” Thrombosis and Haemostasis 59, no. 3 (1988): 349–352. [PubMed] [Google Scholar]
  • 5. Gualtierotti R., Garagiola I., Mortarino M., Spena S., Romero‐Lux O., and Peyvandi F., “Gender Equity in Hemophilia: Need for Healthcare, Familial, and Societal Advocacy,” Frontiers in Medicine (2024): 11:1345496. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6. World Federation of Hemophilia Report on the Annual Global Survey . 2024.
  • 7. Miller C. H., Soucie J. M., Byams V. R., et al., “Women and Girls With Haemophilia Receiving Care at Specialized Haemophilia Treatment Centres in the United States,” Haemophilia 27, no. 6 (2021): 1037–1044. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8. Radhakrishnan N., Pandharipande A., Srivastava A., et al., “A Comparative Analysis of the Bleeding Profile and Quality of Life Among Women with Hemophilia Genotype Compared to Other Bleeding Disorders,” Cureus 16, no. 9 (2024): e68636. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9. Cutter S., Molter D., Dunn S., et al., “Impact of Mild to Severe Hemophilia on Education and Work by US Men, Women, and Caregivers of Children With Hemophilia B: The Bridging Hemophilia B Experiences, Results and Opportunities Into Solutions (B‐HERO‐S) Study,” European Journal of Haematology 98, no. S86 (2017): 18–24. [DOI] [PubMed] [Google Scholar]
  • 10. Buckner T. W., Witkop M., Guelcher C., et al., “Impact of Mild to Severe Hemophilia B on Quality of Life Including Pain and Functional Abilities in Affected Men/Women and Caregivers of Affected Boys/Girls: Analysis of Patient Reported Outcomes in the Bridging Hemophilia B Experiences Results and Opportunities Into Solutions (B‐HERO‐S) Study,” Blood 128, no. 22 (2016): 251–251. [Google Scholar]
  • 11. Balak D. M. W., Gouw S. C., Plug I., et al., “Prenatal Diagnosis for Haemophilia: A Nationwide Survey Among Female Carriers in the Netherlands,” Haemophilia: The Official Journal of the World Federation of Hemophilia 18, no. 4 (2012): 584–592. [DOI] [PubMed] [Google Scholar]
  • 12. Kempton C. L., Guasch S. A., Buckner T. W., Mattis S., and Fedewa S. A., “Differences and Similarities in Patient‐Reported Outcomes Among Men and Women With Haemophilia,” Haemophilia 30, no. 6 (2024): 1383–1392. [DOI] [PubMed] [Google Scholar]
  • 13. Michiels J. J., “Acquired Hemophilia A in Women Postpartum: Clinical Manifestations, Diagnosis, and Treatment,” Clinical and Applied Thrombosis/Hemostasis 6, no. 2 (2000): 82–86. [DOI] [PubMed] [Google Scholar]
  • 14. Plug I., Mauser‐Bunschoten E. P., Bröcker‐Vriends A. H., et al., “Bleeding in Carriers of Hemophilia,” Blood 108, no. 1 (2006): 52–56. [DOI] [PubMed] [Google Scholar]
  • 15. Kronenfeld R. S., Fraga K., Bastos M. L., et al., “Characterization of Joint Disease in Women With Hemophilia: The Carriers Ultrasound Project (CUP) Study,” Blood 142, no. Supplement 1 (2023): 29–29. [Google Scholar]
  • 16. Fraser I. S., Mansour D., Breymann C., Hoffman C., Mezzacasa A., and Petraglia F., “Prevalence of Heavy Menstrual Bleeding and Experiences of Affected Women in a European Patient Survey,” International Journal of Gynaecology and Obstetrics 128, no. 3 (2015): 196–200. [DOI] [PubMed] [Google Scholar]
  • 17. Munro M. G., Mast A. E., Powers J. M., et al., “The Relationship Between Heavy Menstrual Bleeding, Iron Deficiency, and Iron Deficiency Anemia,” American Journal of Obstetrics & Gynecology 229, no. 1 (2023): 1–9. [DOI] [PubMed] [Google Scholar]
  • 18. Say L., Chou D., Gemmill A., et al., “Global Causes of Maternal Death: A WHO Systematic Analysis,” The Lancet Global Health 2, no. 6 (2014): e323–e333. [DOI] [PubMed] [Google Scholar]
  • 19. Puetz J. and Cheng D., “Descriptive Analysis of Bleeding Symptoms in Haemophilia Carriers Enrolled in the ATHNdataset,” Haemophilia: the Official Journal of the World Federation of Hemophilia 27, no. 6 (2021): 1045–1050. [DOI] [PubMed] [Google Scholar]
  • 20. Konkle B. A., Nakaya Fletcher S., “Hemophilia A”, in GeneReviews® [Internet], ed. Adam M. P., Bick S., Mirzaa G. M., et al., (University of Washington, Seattle, 2000), https://www.ncbi.nlm.nih.gov/books/NBK1404/. [Google Scholar]
  • 21. Punt M. C., Waning M. L., Mauser‐Bunschoten E. P., et al., “Maternal and Neonatal Bleeding Complications in Relation to Peripartum Management in Hemophilia Carriers: A Systematic Review,” Blood Reviews 49 (2021): 100826. [DOI] [PubMed] [Google Scholar]
  • 22.d.V.e al., “129 Postpartum Hemorrhage in Hemophilia a and B Carriers After Enhanced Prophylactic Clotting Factor Suppletion: The Pregnancy and Inherited Bleeding Disorders Study (PRIDES),” (ASH, 2024). [Google Scholar]
  • 23. Maas D., Saes J. L., Blijlevens N. M. A., et al., “High Prevalence of Postpartum Hemorrhage in Women With Rare Bleeding Disorders in the Netherlands: Retrospective Data From the RBiN Study,” Journal of Thrombosis and Haemostasis 21, no. 3 (2023): 499–512. [DOI] [PubMed] [Google Scholar]
  • 24. Wiley R. E., Khoury C. P., Snihur A. W. K., et al., “From the Voices of People With Haemophilia A and Their Caregivers: Challenges With Current Treatment, Their Impact on Quality of Life and Desired Improvements in Future Therapies,” Haemophilia 25, no. 3 (2019): 433–440. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25. Krumb E., Lambert C., Van Damme A., Hermans C., et al., “Proactive Systematic Hemophilia Carrier Screening: A Step Towards Gender Equity in Hemophilia Care,” Blood 142, no. Supplement 1 (2023): 288–288. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Available from: Diagnosing Hemophilia | Hemophilia [cited 2025. March 21st]; https://www.cdc.gov/hemophilia/testing/index.html.
  • 27. Arzuaga‐Mendez J., Insunza L., Ojinaga M. J., et al., “Development of a Single‐Tube Reverse Transcription Real‐Time PCR Assay for Diagnosis of F8 Intron 22 Inversion in Patients and Carriers of Haemophilia A,” Haemophilia 31, no. 2 (2025): 263–268. [DOI] [PubMed] [Google Scholar]
  • 28. Srivastava A., Santagostino E., Dougall A., et al., “WFH Guidelines for the Management of Hemophilia, 3rd edition,” Haemophilia 26 no. S6 (2020): 1–158. [DOI] [PubMed] [Google Scholar]
  • 29. Foundation, M.a.S.A.C.o.t.N.H ., Masac Guidelines For Pregnancy And Perinatal Management Of Women With Inherited Bleeding Disorders And Carriers Of Hemophilia A Or B 2021, National Hemophilia Foundation. [Google Scholar]
  • 30. Janbain M. and Kouides P., “Managing Pregnant Women With Hemophilia and von Willebrand Disease: How Do We Provide Optimum Care and Prevent Complications?,” International Journal of Women's Health 14 (2022): 1307–1313. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31. Hirniak S., Edginton A. N., Iorio A., Alsabbagh M. W., Hajducek D. M., and Wong W. W., “Health Utilities in Adults With Hemophilia A: A Retrospective Cohort Study,” Haemophilia 30, no. 3 (2024): 733–742. [DOI] [PubMed] [Google Scholar]
  • 32. Mannucci P. M., “Use of Desmopressin in the Treatment of Hemophilia A: Towards a Golden Jubilee,” Haematologica 103, no. 3 (2018): 379–381. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33. Janneke I. L., Kruip M., Carcao M., et al., “Desmopressin in Moderate Hemophilia A Patients: A Treatment Worth Considering,” Haematologica 103, no. 3 (2018): 550–557. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34. Al Arashi W., Romano L. G. R., Leebeek F. W. G., et al., “Desmopressin to Prevent and Treat Bleeding in Pregnant Women With an Inherited Bleeding Disorder: A Systematic Literature Review,” Journal of Thrombosis and Haemostasis 22, no. 1 (2024): 126–139. [DOI] [PubMed] [Google Scholar]
  • 35. Tengborn L., Blombäck M., and Berntorp E., “Tranexamic Acid—an old Drug Still Going Strong and Making a Revival,” Thrombosis Research 135, no. 2 (2015): 231–242. [DOI] [PubMed] [Google Scholar]
  • 36. Bryant‐Smith A. C., Lethaby A., Farquhar C., and Hickey M., “Antifibrinolytics for Heavy Menstrual Bleeding,” Cochrane Database of Systematic Reviews 4, no. 4 (2018): Cd000249. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37. Leminen H. and Hurskainen R., “Tranexamic Acid for the Treatment of Heavy Menstrual Bleeding: Efficacy and Safety,” International Journal of Women's Health 4 (2012): 413–421. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38. Berntorp E., Follrud C., and Lethagen S., “No Increased Risk of Venous Thrombosis in Women Taking Tranexamic Acid,” Thrombosis and Haemostasis 86, no. 2 (2001): 714–715. [PubMed] [Google Scholar]
  • 39. Shakur H., Elbourne D., Gülmezoglu M., et al., “The WOMAN Trial (World Maternal Antifibrinolytic Trial): Tranexamic Acid for the Treatment of Postpartum Haemorrhage: An International Randomised, Double Blind Placebo Controlled Trial,” Current Controlled Trials in Cardiovascular Medicine 11, no. 1 (2010): 40–40. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40. Chandran R., Tohit E. R. M., Stanslas J., Salim N., Mahmood T. M. T., and Rajagopal M., “Shifting Paradigms and Arising Concerns in Severe Hemophilia a Treatment,” Seminars in Thrombosis and Hemostasis 50, no. 5 (2024): 695–713. [DOI] [PubMed] [Google Scholar]
  • 41. Mannucci P. M., “Hemophilia Treatment Innovation: 50 Years of Progress and More to Come,” Journal of Thrombosis and Haemostasis 21, no. 3 (2023): 403–412. [DOI] [PubMed] [Google Scholar]
  • 42. Poon M.‐C., Lee A., Germini F., et al., “Emicizumab Outcomes in Hemophilia A Using Real‐World Data From the Canadian Hemophilia Bleeding Disorder Registry,” Blood 138 (2021): 347. [Google Scholar]
  • 43. Blair H. A., “Emicizumab: A Review in Haemophilia A,” Drugs 79, no. 15 (2019): 1697–1707. [DOI] [PubMed] [Google Scholar]
  • 44. Rodriguez‐Merchan E. C., de la Corte‐Rodriguez H., and Jimenez‐Yuste V., “Efficacy of Celecoxib in the Treatment of Joint Pain Caused by Advanced Haemophilic Arthropathy in Adult Patients With Haemophilia A,” Haemophilia 20, no. 3 (2014): e225–e227. [DOI] [PubMed] [Google Scholar]
  • 45. Bakeer N., Saied W., Gavrilovski A., and Bailey C., “Haemophilic Arthropathy: Diagnosis, Management, and Aging Patient Considerations,” Haemophilia 30, no. S3 (2024): 120–127. [DOI] [PubMed] [Google Scholar]
  • 46. Di Minno M. N. D., Calcaterra I. L., Baldacci E., et al., “Intensive FVIII Replacement in Hemophilia Patients With Hypertrophic Synovium: A Randomized Study,” Journal of Thrombosis and Haemostasis 23, no. 2 (2025): 458–465. [DOI] [PubMed] [Google Scholar]
  • 47. Schoep M. E., Adang E. M. M., Maas J. W. M., De Bie B., Aarts J. W. M., and Nieboer T. E., “Productivity Loss due to Menstruation‐Related Symptoms: A Nationwide Cross‐Sectional Survey Among 32 748 Women,” BMJ Open 9, no. 6 (2019): e026186. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48. O'Donnell M. J., Abdul Kadir R., van Galen K. P. M., and Lavin M., EAHAD Women and Girls Working Group , “Are Women Welcome in Haemophilia Trials?,” Haemophilia 31, no. 3 (2025): 575–577. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49. Staber J., Croteau S. E., Davis J., Grabowski E. F., Kouides P., and Sidonio R. F. Jr, “The Spectrum of Bleeding in Women and Girls With Haemophilia B,” Haemophilia 24, no. 2 (2018): 180–185. [DOI] [PubMed] [Google Scholar]
  • 50. Sharathkumar A., Hardesty B., Greist A., et al., “Variability in Bleeding Phenotype in Amish Carriers of Haemophilia B With the 31008 C→T Mutation,” Haemophilia 15, no. 1 (2009): 91–100. [DOI] [PubMed] [Google Scholar]
  • 51. Zhu P. and Gu Z., “Observation of the Activity of Factor VIII in the Endometrium of Women With Regular Menstrual Cycles,” Human Reproduction (Oxford) 3, no. 3 (1988): 273–275. [DOI] [PubMed] [Google Scholar]
  • 52. de Vaan A., Goedkoop M. M., Welsing P. M. J., van Hanegem N., Schutgens R. E. G., and van Galen K. P. M., “Clotting Factor Concentration During Menstrual Phases in Women With and Without Heavy Menstrual Bleeding: A Systematic Review and Meta‐Analysis,” Haemophilia 31, no. 4 (2025): 780–786. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Data Availability Statement

Data sharing not appliable to this article as no datasets were generated or analyzed during the current study.


Articles from Haemophilia are provided here courtesy of Wiley

RESOURCES